Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sutetinib - Jiangsu Suzhong Pharmaceutical Group

Next Previous
Drug Profile

Sutetinib - Jiangsu Suzhong Pharmaceutical Group

Alternative Names: Sutetinib maleate; SZMD4 - Jiangsu Suzhong Pharmaceutical Group

Latest Information Update: 23 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Suzhong Pharmaceutical Group
  • Developer Jiangsu Suzhong Pharmaceutical Group; Teligene US
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor modulators; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 18 Oct 2023 Teligene initiates enrolment in a phase II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease) in USA (PO) (NCT06010329)
  • 24 Aug 2023 Teligene plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease) in September 2023 (PO) (NCT06010329)
  • 02 Jun 2023 Efficacy and adverse event data from a phase II trial in Non-small cell ling cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top